Skip to main content
Top
Published in:

Open Access 01-12-2025 | Alzheimer Disease | Research

Differential effects of aging, Alzheimer's pathology, and APOE4 on longitudinal functional connectivity and episodic memory in older adults

Authors: Larissa Fischer, Jenna N. Adams, Eóin N. Molloy, Niklas Vockert, Jennifer Tremblay-Mercier, Jordana Remz, Alexa Pichet Binette, Sylvia Villeneuve, Anne Maass, PREVENT-AD Research Group

Published in: Alzheimer's Research & Therapy | Issue 1/2025

Login to get access

Abstract

Background

Both aging and Alzheimer's disease (AD) affect brain networks, with early disruptions occurring in regions involved in episodic memory. Few studies have, however, focused on distinguishing region-specific effects of AD-biomarker negative “normal” aging and early amyloid- and tau pathology on functional connectivity. Further, longitudinal studies combining imaging, biomarkers, and cognition are rare.

Methods

We assessed resting-state functional connectivity (rsFC) strength and graph measures in the episodic memory network including the medial temporal lobe (MTL), posteromedial cortex (PMC), and medial prefrontal cortex alongside cognition over two years. For this preregistered study, we included 100 older adults who were amyloid- and tau-negative using CSF and PET measurements to investigate “normal” aging, and 70 older adults who had longitudinal CSF data available to investigate functional changes related to early AD pathology. All participants were cognitively unimpaired older adults from the PREVENT-AD cohort. We used region of interest (ROI)-to-ROI bivariate correlations, graph analysis, and multiple regression models.

Results

In the amyloid- and tau-negative sample, rsFC strength within PMC, between parahippocampal cortex and inferomedial precuneus, and between posterior hippocampus and inferomedial precuneus decreased over time. Additionally, we observed a longitudinal decrease in global efficiency. Further, there was a steeper longitudinal decrease in rsFC and global efficiency with higher baseline age particularly of parahippocampal-gyrus regions. Further, lower rsFC strength within PMC was associated with poorer longitudinal episodic memory performance. In the sample with available CSF data, a steeper increase in rsFC between anterior hippocampus and superior precuneus was related to higher baseline AD pathology. Higher MTL-PMC rsFC strength was differentially associated with episodic memory trajectories depending on APOE4 genotype.

Conclusions

Our findings suggest differential effects of aging and AD pathology. Hypoconnectivity within PMC was related to aging and cognitive decline. MTL-PMC hyperconnectivity was related to early AD pathology and cognitive decline in APOE4 carriers. Future studies should investigate more diverse samples, nonetheless, our approach allowed us to identify longitudinal functional changes related to aging and early AD pathology, enhancing cross-sectional research. Hyperconnectivity has been proposed as a mechanism related to early AD pathology before, we now contribute specific functional connections to focus on in future research.

Graphical Abstract

A) “Normal aging” in cognitively unimpaired older adults with a negative amyloid- and tau- biomarker status was characterized by a longitudinal decrease in functional connectivity strength. B) Cognitively unimpaired older adults with more Alzheimer’s pathology at baseline (measured via cerebrospinal fluid) exhibited a longitudinal increase in functional connectivity strength.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Differential effects of aging, Alzheimer's pathology, and APOE4 on longitudinal functional connectivity and episodic memory in older adults
Authors
Larissa Fischer
Jenna N. Adams
Eóin N. Molloy
Niklas Vockert
Jennifer Tremblay-Mercier
Jordana Remz
Alexa Pichet Binette
Sylvia Villeneuve
Anne Maass
PREVENT-AD Research Group
Publication date
01-12-2025
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2025
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-025-01742-6

EAN 2025

Unlock your free and exclusive access to the latest news and expert interviews from the European Academy of Neurology's annual congress.

Read more

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest